Innovative Medicine — Selling, marketing and administrative expenses
Business Segments · Selling, marketing and administrative expensesJohnson & Johnson Innovative Medicine — Selling, marketing and administrative expenses increased by 2.9% to $2.87B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 15.2%, from $2.49B to $2.87B. Over 2 years (FY 2022 to FY 2024), Innovative Medicine — Selling, marketing and administrative expenses shows an upward trend with a 6.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
High spending may be necessary for new product launches, but excessive spending relative to revenue growth may signal inefficiency.
Detailed definition
Captures the operating expenses related to the sales force, marketing campaigns, and administrative support for the Inno...
Peer comparison
Standard 'SG&A' expense allocation for business segments in the pharmaceutical industry.
jnj_segment_innovative_medicine_selling_marketing_and_administrative_expensesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.43B | $2.43B | $2.43B | $2.43B | $2.46B | $2.46B | $2.46B | $2.46B | $2.44B | $2.67B | $2.49B | $3.31B | $2.26B | $2.79B | $2.87B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +1.3% | +0.0% | +0.0% | +0.0% | -0.9% | +9.3% | -6.5% | +33.0% | -31.7% | +23.4% | +2.9% |
| YoY Change | — | — | — | — | +1.3% | +1.3% | +1.3% | +1.3% | -0.9% | +8.3% | +1.2% | +34.6% | -7.3% | +4.7% | +15.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's innovative medicine — selling, marketing and administrative expenses?
- Johnson & Johnson (JNJ) reported innovative medicine — selling, marketing and administrative expenses of $2.87B in Q3 2025.
- How has Johnson & Johnson's innovative medicine — selling, marketing and administrative expenses changed year-over-year?
- Johnson & Johnson's innovative medicine — selling, marketing and administrative expenses increased by 15.2% year-over-year, from $2.49B to $2.87B.
- What is the long-term trend for Johnson & Johnson's innovative medicine — selling, marketing and administrative expenses?
- Over 2 years (2022 to 2024), Johnson & Johnson's innovative medicine — selling, marketing and administrative expenses has grown at a 6.0% compound annual growth rate (CAGR), from $9.71B to $10.91B.
- What does innovative medicine — selling, marketing and administrative expenses mean?
- The costs of selling, marketing, and managing the Innovative Medicine business.